Aglaia Oncology Funds

Aglaia Oncology Funds is a Dutch investment firm dedicated to advancing oncology drug development by selecting and maturing early-stage breakthrough inventions that transform cancer treatment. Founded in 2004, the company leverages decades of research experience to guide portfolio companies from initial screening through clinical studies toward licensing or acquisition.

• Services: The team provides hands-on strategic direction and designs comprehensive research plans ranging from animal feasibility studies to full-scale clinical trials.
• Industries: Aglaia focuses exclusively on oncology, having been involved in the development of over 100 potential cancer treatment products.
• Sustainability: Since 2016, the firm utilizes a Life Sciences Impact Suite containing 50 indicators to measure socio-economic and clinical performance across its investments.

The organization has successfully transitioned numerous early-stage ventures into clinically mature candidates ready for market entry or sale.